接近所有异构体:使用羧酸铑 (II) 催化剂可从邻位取代芳基叠氮化物中轻松获得一系列 α-、β- 和 δ-咔啉鎓离子(参见方案)。咔啉离子很容易被还原以提供色氨酸或去质子化以获取吡啶并吲哚。这种 [Rh II 2 ]-催化的 C H 键胺化用于合成 (±)-horsfiline 和新隐碱。esp=α,α,α',α'-四甲基-1,3-苯二丙酸酯。
接近所有异构体:使用羧酸铑 (II) 催化剂可从邻位取代芳基叠氮化物中轻松获得一系列 α-、β- 和 δ-咔啉鎓离子(参见方案)。咔啉离子很容易被还原以提供色氨酸或去质子化以获取吡啶并吲哚。这种 [Rh II 2 ]-催化的 C H 键胺化用于合成 (±)-horsfiline 和新隐碱。esp=α,α,α',α'-四甲基-1,3-苯二丙酸酯。
[EN] FACTOR XIa INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR XIA
申请人:MERCK SHARP & DOHME
公开号:WO2016015593A1
公开(公告)日:2016-02-04
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists.
The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.
本发明涉及调节各种趋化因子受体的化合物。这些化合物可用于治疗炎症和免疫性疾病。
ARYL SULFONAMIDES
申请人:Ungashe Solomon
公开号:US20110201610A1
公开(公告)日:2011-08-18
The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.
本发明涉及调节多种趋化因子受体的化合物。这些化合物可用于治疗炎症和免疫疾病。
Aryl sulfonamides
申请人:ChemoCentryx, Inc.
公开号:US07932252B2
公开(公告)日:2011-04-26
The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.